Lubiprostone: viewpoints

Drugs. 2006;66(6):880-1. doi: 10.2165/00003495-200666060-00017.
No abstract available

Publication types

  • Comment

MeSH terms

  • Alprostadil / adverse effects
  • Alprostadil / analogs & derivatives*
  • Alprostadil / therapeutic use
  • CLC-2 Chloride Channels
  • Cathartics / adverse effects
  • Cathartics / therapeutic use
  • Chloride Channel Agonists
  • Chloride Channels / physiology
  • Constipation / drug therapy*
  • Fatty Acids / adverse effects
  • Fatty Acids / therapeutic use*
  • Female
  • Humans
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / physiology
  • Lubiprostone
  • Male

Substances

  • CLC-2 Chloride Channels
  • Cathartics
  • Chloride Channel Agonists
  • Chloride Channels
  • Fatty Acids
  • Lubiprostone
  • Alprostadil